Gain Intelligence on Royalties, Settlements, and More with Drug Patent Litigation Information

Disclosure: the majority of the companies mentioned below are, or have been, clients of DrugPatentWatch Drug patent litigation can be used for many aspect of biopharmaceutical business strategy. Many parties…
The post Gain Intelligence on Royalties, Se…


How Pharmacists Are Trapped in the Middle of Drug Price Wars

Pharmacists, as the interface between the general public and prescription drug manufacturers, can sometimes feel as if they’re treading a fine line between fulfilling their obligations to pharmaceutical companies and…
The post How Pharmacists Are Trapp…


How to Use Tentative Drug Approvals to Anticipate Generic Entry

Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …


How to Use Tentative Drug Approvals to Anticipate Generic Entry

Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …


Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study

This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…


Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…


Make better decisions with advanced biopharmaceutical business intelligence

What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and the strength of the DrugPatentWatch platform to develop a solution…
The post Make better decisions with advanced biopharmaceutical busin…


Driving Innovation: Drug Patents vs. Prizes

Joseph E Stiglitz, American economist and professor at Columbia University, states that prizes should be favored over patents to reward and stimulate innovation. The uniqueness of the patent system referred…
The post Driving Innovation: Drug Patents vs…


Drug Patent Expirations for the Week of July 29, 2018

SPIRIVA (tiotropium bromide) Boehringer ingelheim Patent: RE39820 Expiration: Jul 30, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]
The post…


New patent expiration for Gilead drug LETAIRIS

Annual Drug Patent Expirations for LETAIRIS Letairis is a drug marketed by Gilead and is included in one NDA. It is available from one supplier. There are four patents protecting…
The post New patent expiration for Gilead drug LETAIRIS appeared first o…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: